Research and Markets has announced the addition of the "Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016" report to their offering.
Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 1 and 7 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.
Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/72xh9r/melanocortin
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006460/en/Business Wire
Last updated on: 27/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.